The country of origin of Ibuprofen and Famotidine Tablets imported in dosage form
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the country of origin of the Ibuprofen and Famotidine Tablets will be India, where the mixing of the active ingredients Ibuprofen (made in India) and Famotidine (made in India) with the inactive ingredients from various countries into the final tablet in dosage form are made.
Ruling text
In your letter dated July 17, 2025, you requested a country of origin ruling. Ibuprofen and Famotidine Tablets is a medicinal preparation containing a combination of 800 mg of Ibuprofen (nonsteroidal anti-inflammatory drug (NSAID)), and 26.6 mg of Famotidine (histamine H2-receptor antagonist), as the active ingredients. It is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.
In your letter, you stated Ibuprofen and Famotidine Tablets contain two active pharmaceutical ingredients (APIs). The Ibuprofen is made in India, and the Famotidine is also made in India. In India, these two APIs will be mixed with inactive ingredients from various countries to produce the final Ibuprofen and Famotidine tablets in dosage form.
Section 134.1(b), Customs Regulations (19 CFR 134.1(b)), defines "country of origin" as: The country of manufacture, production or growth of any article of foreign origin entering the United States. Further work or material added to an article in another country must effect a substantial transformation in order to render such other country the "country of origin" within the meaning of this part; ….
A substantial transformation occurs when an article emerges from a process with a new name, character or use different from that possessed by the article prior to processing. A substantial transformation will not result from a minor manufacturing or combining process that leaves the identity of the article intact. See United States v. Gibson-Thomsen Co., 27 C.C.P.A. 267 (1940); and National Juice Products Association v. United States, 628 F. Supp. 978 (Ct. Int’l Trade 1986).
In determining whether a substantial transformation occurs in the manufacture of chemical products such as pharmaceuticals, CBP has consistently examined the complexity of the processing and whether the final article retains the essential identity and character of the raw material. To that end, CBP has generally held that the processing of pharmaceutical products from bulk form into measured doses does not result in a substantial transformation of the product.
See, e.g., Headquarters Ruling (“HQ”) 561975, dated April 3, 2002; HQ 561544, dated May 1, 2000; HQ 735146, dated November 15, 1993; HQ H267177, dated November 5, 2016; HQ H233356, dated December 26, 2012; and, HQ 561975, dated April 3, 2002. However, where the processing from bulk form into measured doses involves the combination of two or more APIs, and the resulting combination offers additional medicinal benefits compared to taking each API alone, CBP has held that a substantial transformation occurred.
See, e.g., HQ 563207, dated June 1, 2005. In this instance we note that the two APIs serve different purposes. Here, as in HQ 563207, two separate APIs are mixed to create a fixed combination drug that offers additional medicinal benefits compared to taking each API alone. The Ibuprofen allows patients to manage their pain and inflammation while the Famotidine reduces the risk of developing gastrointestinal issues associated with NSAID use.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N351439).